Phase i/ii study of docetaxel (DOC) and carboplatin (CBDCA) with concurrent radiotherapy in patients with stage III unresectable non-small cell lung cancer (NSCLC), preliminary results
Shingo Kato, Seiji Kosaihira, Tomoko Kazumoto, Yukio Noguchi(Saitama Cancer Center), Satoshi Yoneda, Hitoshi Sakai, Mizuaki Sakura, Shinobu Honda, Keigo Kobayashi(Osaka Gakuin University)
Cited by 0
Related Papers
A cross-validation of the European organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with Lung Cancer
|European Journal of Cancer|1998|255
High Pressure NQR Measurement in CeCu<sub>2</sub>Si<sub>2</sub> up to Sudden Disappearance of Superconductivity
|Journal of the Physical Society of Japan|2008|78
Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis
|Clinical Lung Cancer|2018|55
Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare <i>EGFR</i> mutations
|Proceedings of the National Academy of Sciences|2019|54